专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明公开

EP1108434A1 DRUGS FOR RELIEVING CARBONYL STRESS AND PERITONEAL DIALYSATES 有权
标题翻译： ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE ATE
公开(公告)号：EP1108434A1
公开(公告)日：2001-06-20
申请号：EP99938581.8
申请日：1999-08-23
申请人： Kurokawa, Kiyoshi , Miyata, Toshio
发明人： MIYATA, Toshio
IPC分类号： A61K45/00 , A61K31/155 , A61K31/15 , A61K33/44 , A61K31/44 , A61K31/195 , A61K38/38 , A61M1/28
CPC分类号： A61K31/203 , A61K31/155 , A61K31/4965 , A61K33/00 , A61M1/287 , Y10S514/832 , Y10S514/866 , A61K2300/00
摘要： Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds transferred from the blood to the peritoneal cavity of the patient during peritoneal dialys is treatment, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. Intraperitoneal protein modification by carbonyl compounds is inhibited by the present invention, thereby sufficiently reducing peritoneal disorders associated with peritoneal dialysis treatment.
摘要翻译：产生并积累在腹膜透析液中的羰基化合物可以被羰基化合物捕获剂如氨基胍灭活或消除。消毒和储存腹膜透析液期间产生的羰基化合物可以通过与捕获剂预接触来消除。此外，可以通过将腹膜透析液中的捕获剂加入或通过使羰基化合物捕获筒循环来除去在腹膜透析治疗期间从血液转移到腹膜腔的羰基化合物。本发明抑制羰基化合物的腹膜内蛋白质修饰，从而充分降低与腹膜透析治疗相关的腹膜障碍。

82. 发明公开

EP1011655A1 INHIBITORS OF LEADERLESS PROTEIN EXPORT 失效
标题翻译：消除蛋白群龙无首的抑制剂的
公开(公告)号：EP1011655A1
公开(公告)日：2000-06-28
申请号：EP98907634.4
申请日：1998-02-25
申请人： Ciblex Corporation
发明人： FLORKIEWICZ, Robert, Z. , BAIRD, Andrew
IPC分类号： A61K31/18 , A61K31/645 , A61K31/19 , A61K31/165 , A61K31/38 , A61K31/15 , A61K31/52 , A61K31/27 , A61K31/215
CPC分类号： A61K31/00 , A61K31/15 , A61K31/167 , A61K31/18 , A61K31/19 , A61K31/216 , A61K31/27 , A61K31/382 , A61K31/52 , G01N33/68
摘要： Methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a compound that inhibits the binding of the leaderless protein and a transport molecule are provided. Leaderless proteins include FGF-1, FGF-2, IL-1α, IL-1β, CNTF and HIV-tat. These methods are useful in treatment of various conditions, including tumors and diabetes.

83. 发明公开

EP0994848A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS 失效
标题翻译： ANTAGONISTEN BZW. AGONISTEN VON GLUKAGON
公开(公告)号：EP0994848A1
公开(公告)日：2000-04-26
申请号：EP98929244.6
申请日：1998-07-01
申请人： NOVO NORDISK A/S , AGOURON PHARMACEUTICALS, INC.
发明人： GONZALES, Javier , SAMS, Christian , TENG, Min , LING, Anthony , GREGOR, Vlad , HONG, Yufeng , KIEL, Dan , KUKI, Atsuo , SHI, Shenghua , NAERUM, Lars , MADSEN, Peter , LAU, Jesper , PLEWE, Michael, Bruno , FENG, Jun , JOHNSON, Michael, David , TESTON, Kimberly, Ann , SIDELMANN, Ulla, Grove , KNUDSEN, Lotte, Bjerre
IPC分类号： C07C243/18 , C07D209/04 , A61K31/15 , A61K31/40
CPC分类号： C07D209/48 , C07C251/86 , C07C255/29 , C07C309/65 , C07C311/49 , C07C317/28 , C07C323/45 , C07C2601/02 , C07C2601/14 , C07D209/86 , C07D213/30 , C07D213/80 , C07D215/12 , C07D231/12 , C07D295/185 , C07D307/12 , C07D307/52 , C07D309/06 , C07D317/58
摘要： Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof. The compounds act to antagonize the action of the glucagon peptide hormone.
摘要翻译：包含中心酰肼基序的非肽化合物及其合成方法。该化合物用于拮抗胰高血糖素肽激素的作用。

84. 发明公开

EP0767661A4 AZAASPARTIC ACID ANALOGS AS INTERLEUKIN-1 BETA CONVERTING ENZYME INHIBITORS 失效
标题翻译： AZAASPARAGINSÄUREANALOGAAS白细胞介素-1β转化酶抑制剂的
公开(公告)号：EP0767661A4
公开(公告)日：1998-06-10
申请号：EP95928696
申请日：1995-07-31
申请人： SANOFI WINTHROP INC
发明人： DOLLE ROLAND E , GRAYBILL TODD L
IPC分类号： C07D231/22 , A61K31/195 , A61K31/198 , A61K31/215 , A61K31/27 , A61K31/40 , A61K31/66 , A61K38/00 , A61P11/00 , A61P25/00 , A61P29/00 , A61P37/00 , A61P43/00 , C07C243/24 , C07C243/28 , C07C243/34 , C07C243/38 , C07D307/60 , C07F9/32 , C07K5/06 , C07K5/083 , A61K31/15 , A61K31/22 , A61K31/235 , A61K31/34 , A61K31/415 , A61K38/05 , A61K38/06 , C07K5/02 , C07K5/062
CPC分类号： C07K5/0808 , A61K38/00 , C07C243/28 , C07C243/34 , C07C243/38 , C07K5/06052

85. 发明授权

EP0636368B1 The use of 2- phenylmethylene -1- 3'-(amino)-2'-(hydroxy)--propoxy-imino -cyclohexane derivatives 失效
标题翻译：使用2-苯基亚甲基-1-3“的 - （氨基）-2-（羟基） - 丙氧基亚氨基环己烷衍生物
公开(公告)号：EP0636368B1
公开(公告)日：1997-12-10
申请号：EP94111107.2
申请日：1994-07-18
申请人： EGIS GYOGYSZERGYAR RT.
发明人： Szirt, geb. Kiszelly, Enikö , Budai, Zoltan, Dr. , Mezei, Tibor, Dr.. , Blasko, Gabor, Dr. , Kazo, geb. Daroczi, Klara , Egyed, Andras, Dr. , Gigler, Gabor , Fekete, Marton, Dr. , Reiter, geb. Esses, Klara, Dr. , Simig, Gyula, Dr. , Szemerédi, Katalin, Dr.
IPC分类号： A61K31/15 , A61K31/495
CPC分类号： A61K31/15 , A61K31/495

86. 发明授权

EP0728739B1 Composés bi-aromatiques dérivés d'amide, compositions pharmaceutiques et cosmétiques les contenant et utilisations 失效
标题翻译：双向的芳香酰胺衍生物，这些含药物和化妆品组合物及其用途
公开(公告)号：EP0728739B1
公开(公告)日：1997-11-05
申请号：EP96400251.3
申请日：1996-02-06
申请人： CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA)
发明人： Bernardon, Jean-Michel , Vigne, Laurence, Résidence Paradis Parc, Bât A
IPC分类号： C07C251/54 , C07C251/48 , C07C251/56 , C07C251/58 , C07C233/00 , C07C235/00 , C07C237/00 , A61K31/15 , A61K7/48 , A61K7/06
CPC分类号： C07C251/60 , A61K8/42 , A61K8/44 , A61K8/445 , A61K8/4926 , A61K8/4973 , A61K8/4986 , A61K8/671 , A61Q5/00 , A61Q19/00 , C07C233/55 , C07C251/48 , C07C251/54 , C07C2602/10 , Y10S514/844 , Y10S514/864 , Y10S514/88 , Y10S514/886

87. 发明公开

EP0789566A4 EP0789566A4 - 失效
标题翻译： EP0789566A4 - Google专利
公开(公告)号：EP0789566A4
公开(公告)日：1997-09-10
申请号：EP95938169
申请日：1995-10-18
IPC分类号： A61K38/00 , A61K31/16 , A61K31/66 , A61P43/00 , C07C243/24 , C07C243/40 , C07C271/20 , C07D213/81 , C07D213/82 , C07D307/20 , C07D309/12 , A61K31/15
CPC分类号： C07D213/81 , C07C243/40 , C07C271/20 , C07C2601/02 , C07C2601/14 , C07D213/82 , C07D307/20 , C07D309/12
摘要： This invention relates to a class of aminimides structurally characterized as an acyl nitrogen-nitrogen ylide such that the acyl moiety possesses the structural diversity element G, the quaternary nitrogen possesses structural diversity elements E and F, and the quaternary nitrogen is bonded to a hydroxyethyl substituent, which in turn is bonded to an aminomethylene moiety that possesses structural diversity elements A and B from the amino group and diversity element C from the methylene substituent, as shown in chemical formula (I), wherein structural diversity elements A, B, C, D, E, F and G are chosen from the set of elements consisting of substituted and unsubstituted as well as branched and straight chain alkyl, aryl, alkaryl, aralkyl, carbocyclic, heterocyclic, hydrogen, amino acid, peptide, polypeptide, protein, depsipeptide, carbohydrate derivatives, nucleotide derivatives, oligonucleotide derivatives, naturally occurring or synthetic organic structural motifs, reporter elements, organic moieties containing at least one polymerizable group, macromolecular component, resin, silicate, other surface and particle support, the diversity elements can be the same, can be different, and can also be connected to form a ringed to several ringed species.
摘要翻译：本发明涉及一类在结构上表征为酰基氮 - 氮叶立德的氨基酰亚胺，使得酰基部分具有结构多样性元素G，季氮具有结构多样性元素E和F，并且季氮与羟乙基取代基如化学式（I）所示，其中结构多样性元素A，B，C，C，C，D和E分别结合到具有来自氨基的结构多样性元素A和B和来自亚甲基取代基的多样性元素C的氨基亚甲基部分。 D，E，F和G选自取代和未取代以及支链和直链烷基，芳基，烷芳基，芳烷基，碳环，杂环，氢，氨基酸，肽，多肽，蛋白质，缩酚酸肽，碳水化合物衍生物，核苷酸衍生物，寡核苷酸衍生物，天然存在的或合成的有机结构基元，报道元件 s，含有至少一个可聚合基团的有机部分，大分子组分，树脂，硅酸盐，其他表面和颗粒载体，多样性元素可以是相同的，可以是不同的，并且也可以连接以形成环状到多个环状物种。

88. 发明公开

EP0619298A2 (Phenylmethylene)-2-(alkyl)-1- omega-(amino)-alkoxyimino -cycloalkane derivatives, a process for preparing them as well as medicaments containing them and the use of them 失效
标题翻译：（苯基亚甲基）-2-（烷基）-1-ω-（氨基）-alkoxyimino-cyloalkan衍生物，它们的制备方法和含有它们的药物和它们的用途。
公开(公告)号：EP0619298A2
公开(公告)日：1994-10-12
申请号：EP94105516.2
申请日：1994-04-11
申请人： EGIS GYOGYSZERGYAR RT.
发明人： Bajnogel, Judit Dr. , Blasko, Gábor Dr. , Budai, Zoltán Dr. , Egyed, András Dr. , Fekete, Márton Dr. , Karaffa, Erika chemist , Mezei, Tibor Dr. , Reiter, Klára Dr. , Simig, Gyula Dr. , Szemerédi, Katalin Dr. , Szirt, Enikö biologist
IPC分类号： C07C251/58 , C07D295/12 , A61K31/15 , A61K31/445 , A61K31/495
CPC分类号： C07D295/088 , C07C251/58 , C07C2601/08 , C07C2601/14 , C07C2601/18 , Y10S514/925 , Y10S514/926 , Y10S514/927 , Y10S514/928
摘要： A subject-matter of the invention are (phenylmethylene)-2-(alkyl)-1-[ω-(amino)-alkoxyimino]-cycloalkane derivatives of general formula

wherein

R represents hydrogen, C₁₋₄ alkyl or hydroxyl,
R₁ stands for C₁₋₁₂ alkyl,
R₂ and R₃ independently each represents hydrogen, a C₁₋₁₂ alkyl group, optionally substituted by hydroxy, or a C₂₋₁₂ alkenyl group,
or
R₂ and R₃ together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring, optionally comprising an oxygen, sulfur or a further nitrogen atom, which latter optionally may carry a phenyl, benzyl or C₁₋₄ alkyl substituent,
R₄ and R₅ independently each stands for hydrogen, halogen or a C₁₋₄ alkoxy group, or together represent a 3,4-methylenedioxy group,
n is an integer from 2 to 5
and
A represents a valency bond or a -CH₂-group,
as well as stereo and optically active isomers and their mixtures, acid-addition salts and quaternary ammonium derivatives thereof.
Furthermore the invention is concerned with a process for preparing these compounds as well as medicaments containing them and the use of them for preparing medicaments, particularly having ulcus and gastric-acid-secretion inhibiting effects.
摘要翻译：本发明的主题是：（苯基亚甲基）-2-（烷基）-1- [Ω - （氨基）烷氧基亚氨基]通式 worinřdarstellt氢，C1-4烷基或羟基的环烷烃衍生物， R1代表C1-12烷基，R2和R3各自unabhängigdarstellt氢，C 1-12烷基，任选地被羟基，或C 2-12一链烯基，或R2和R3一起与氮原子substituiertem到它们所连接氢形成4-至7-元杂环，其任选地包含氧，硫或氮原子。此外，后一种可任选地携带一个苯基，苄基或C 1-4烷基取代基，R4和R5各自独立地代表卤素或 C1-4烷氧基，或一起代表3,4-亚甲二氧基，n为2〜5的整数和A价键或一个darstellt -CH 2基团，以及立体声和旋光异构体及其混合物，酸加成盐和季铵衍生物。进一步，本发明涉及有用于制备合成化合物以及含有它们的药物和用于制备药物的用途其中，特别是具有ulcus和胃酸分泌抑制效果的方法。

89. 发明公开

EP0589039A1 TRIPHENYLETHYLENE DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME 失效
标题翻译：三苯基乙烯衍生物和含有它的药物制剂
公开(公告)号：EP0589039A1
公开(公告)日：1994-03-30
申请号：EP92908856.5
申请日：1992-04-30
申请人： Asahi Kasei Kogyo Kabushiki Kaisha
发明人： KOUJI, Hiroyuki , ANDO, Satoshi
IPC分类号： C07C217/14 , C07C217/28 , C07C217/42 , C07C219/06 , C07C251/32 , C07D295/08 , C07D317/50 , C07F9/12 , A61K31/135 , A61K31/15 , A61K31/36
CPC分类号： C07D295/088 , C07C217/18 , C07C217/30 , C07C217/34 , C07C217/42 , C07C219/06 , C07C251/48 , C07C251/60 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D317/50 , C07D317/54 , C07F9/12 , C07F9/65517 , C07F9/65586
摘要： A triphenylalkene derivative represented by general formula (1), a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutical composition thereof having a tumor inhibitory action and an osteoporosis curing activity. In general formula (1) R₁ represents a group selected among those represented by formulae (2), (3) and (4); R₆ and R₇ represent each hydrogen, alkyl or cycloalkyl, or R₆ and R₇ together form a heterocyclic group with the adjacent nitrogen atom, provided that R₆ and R₇ should not be hydrogen atoms at the same time; R₈ represents hydrogen or alkylcarbonyl; R₂ represents alkyl or cycloalkyl; R₃ represents phenyl or 3,4-methylenedioxyphenyl, provided that when R₃ represents phenyl, the case where R₁ represents a group of formula (4) is excluded; R₄ represents hydrogen, hydroxyl, R₉C(O)O-, R₁₀OCH₂O-, -OPO(OH)₂ or CH = NOR₁₁; R₉ represents alkyl; R₁₀ represents alkyl or alkylcarbonyl; R₅ represents hydrogen or CH = NOR₁₁; and R₁₁ represents hydrogen, alkyl or substituted alkyl.
摘要翻译：通式（1）表示的三苯基烯烃衍生物，其药学上可接受的酸加成盐及其药物组合物，具有肿瘤抑制作用和骨质疏松症治疗活性。在通式（1）中，R 1表示选自由式（2），（3）和（4）表示的基团; R 6和R 7各自代表氢，烷基或环烷基，或R 6和R 6与相邻的氮原子一起形成杂环基，条件是R 6和R 6不应同时为氢原子; R 6代表氢或烷基羰基; R 2代表烷基或环烷基; R 3代表苯基或3,4-亚甲二氧基苯基，条件是当R 3代表苯基时，排除R 1代表式（4）基团的情况; R 4代表氢，羟基，R 8 C（O）O-，R 10 OCH 2 O-，-OPO（OH）2或CH = NOR 11; R 6代表烷基; R 10代表烷基或烷基羰基; R 5代表氢或CH = NOR 11; 和R 11代表氢，烷基或取代的烷基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式